Payment overview · 2025
General Payments
$198.44
12 reported records · 7 companies
Healthcare provider profile · identity verified
Trung Dien Tran, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ATLANTA, GA · NPI 1932202983
Verified facts
What the public records show
CMS Open Payments records show Trung Dien Tran, MD received $198.44 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 31.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.96 | 31.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.30 | 18.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.57 | 15.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.62 | 11.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.82 | 8.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.11 | 7.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.06 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $198.44 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.96 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.60 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $37.30 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.57 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 128 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
46 | 30 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 902 | 301 |
| Amlodipine Besylate | Amlodipine Besylate | 567 | 188 |
| Losartan Potassium | Losartan Potassium | 344 | 111 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 234 | 137 |
| Metformin Hcl | Metformin Hcl | 213 | 73 |
| Metformin Hcl Er | Metformin Hcl | 213 | 81 |
| Diclofenac Sodium | Diclofenac Sodium | 186 | 69 |
| Omeprazole | Omeprazole | 169 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 169 | 53 |
| Alendronate Sodium | Alendronate Sodium | 163 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 56 |
| Gabapentin | Gabapentin | 142 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 133 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 131 | 39 |
| Jardiance | Empagliflozin | 128 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 46 |
| Glipizide | Glipizide | 121 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 118 | 34 |
| Meloxicam | Meloxicam | 118 | 91 |
| Lisinopril | Lisinopril | 98 | 36 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 89 | 32 |
| Donepezil Hcl | Donepezil Hcl | 88 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 84 | 38 |
| Famotidine | Famotidine | 83 | 40 |
| Glipizide Er | Glipizide | 80 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 75 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 23 |
| Nifedipine Er | Nifedipine | 74 | 26 |
| Meclizine Hcl | Meclizine Hcl | 64 | 43 |
| Prednisone | Prednisone | 58 | 50 |
| Azithromycin | Azithromycin | 54 | 49 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 16 |
| Carvedilol | Carvedilol | 52 | 15 |
| Ezetimibe | Ezetimibe | 50 | 16 |
| Mirtazapine | Mirtazapine | 50 | 19 |
| Montelukast Sodium | Montelukast Sodium | 50 | 19 |
| Trazodone Hcl | Trazodone Hcl | 50 | 23 |
| Allopurinol | Allopurinol | 49 | 13 |
| Baclofen | Baclofen | 49 | 36 |
| Simvastatin | Simvastatin | 49 | 18 |
| Vascepa | Icosapent Ethyl | 48 | 11 |
| Prolia | Denosumab | 46 | 30 |
| Farxiga | Dapagliflozin Propanediol | 45 | 12 |
| Januvia | Sitagliptin Phosphate | 44 | 15 |
| Mometasone Furoate | Mometasone Furoate | 41 | 22 |
| Finasteride | Finasteride | 40 | 16 |
| Atenolol | Atenolol | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 36 | 12 |
| Lovastatin | Lovastatin | 35 | 12 |
| Tradjenta | Linagliptin | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | 13 |
| Telmisartan | Telmisartan | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | 11 |
| Fenofibrate | Fenofibrate | 26 | 12 |
| Ketoconazole | Ketoconazole | 26 | 15 |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Colchicine | Colchicine | 23 | 13 |
| Cromolyn Sodium | Cromolyn Sodium | 22 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Eliquis | Apixaban | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $198.44 · 12 records | Novo Nordisk Inc | Cologuard Collection Kit, JARDIANCE, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, ZEPBOUND, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error